However, a combination of two ECM proteins (EFEMP1 and FSTL3) and E/e' proved to be powerful predictors of MACE and HF risk, and both protein markers can be explored as potential therapeutic targets in post-MI patients given the emerging evidence (27–30). The gene discussed is EFEMP1; the disease is myocardial infarction.